Beximco Pharmagdr Regs Stock Total Debt
| R2WA Stock | EUR 0.41 0.00 0.00% |
BEXIMCO PHARMAGDR REGS fundamentals help investors to digest information that contributes to BEXIMCO PHARMAGDR's financial success or failures. It also enables traders to predict the movement of BEXIMCO Stock. The fundamental analysis module provides a way to measure BEXIMCO PHARMAGDR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BEXIMCO PHARMAGDR stock.
BEXIMCO |
BEXIMCO PHARMAGDR REGS Company Total Debt Analysis
BEXIMCO PHARMAGDR's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, BEXIMCO PHARMAGDR REGS has a Total Debt of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-Specialty & Generic (which currently averages 0.0) industry. The total debt for all Germany stocks is 100.0% higher than that of the company.
BEXIMCO Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BEXIMCO PHARMAGDR's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BEXIMCO PHARMAGDR could also be used in its relative valuation, which is a method of valuing BEXIMCO PHARMAGDR by comparing valuation metrics of similar companies.BEXIMCO PHARMAGDR is currently under evaluation in total debt category among its peers.
BEXIMCO Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.14 % | |||
| Shares Outstanding | 446.11 M | |||
| Shares Owned By Institutions | 2.09 % | |||
| Gross Profit | 15.71 B | |||
| Debt To Equity | 27.50 % | |||
| Current Ratio | 2.26 X | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 563.15 M | |||
| Annual Yield | 0.06 % |
About BEXIMCO PHARMAGDR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BEXIMCO PHARMAGDR REGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BEXIMCO PHARMAGDR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BEXIMCO PHARMAGDR REGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BEXIMCO Stock
BEXIMCO PHARMAGDR financial ratios help investors to determine whether BEXIMCO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BEXIMCO with respect to the benefits of owning BEXIMCO PHARMAGDR security.